Cardinal Health's stock has surged 133% since May 2022, but its long-term chart reveals a history of prolonged correction.

Welcome to the Rani Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following management's ...

Jim Cramer sees signs of market health, despite doomsday Wall Street whispers. He marvels at how various overlooked ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Linda Bethea details how the marketer of brands including Oikos and Silk is approaching emerging channels and artificial ...

As the indications and demand for glucagon-like peptide-1 (GLP-1) agonist drugs continue to expand, the real-world GLP-1 research and data-driven insights from Prime Therapeutics LLC (Prime) help ...

Could a diabetes drug slash your cancer risk? New research shows GLP-1 receptor agonists may protect patients with type 2 diabetes from deadly blood cancers—beyond just managing blood sugar.

ST. LOUIS — As GLP-1 weight-loss drugs become more prevalent, some consumer packaged goods (CPG) companies have added products to the market touting GLP-1-friendly nutrition formulations in ...

SAN DIEGO, March 23, 2025 — Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss. Unfortunately, shortages and high costs have ...

CHICAGO — In patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, chronic kidney disease, or both, the oral formulation of semaglutide, a glucagon-like ...